Botulinum Toxin in the Treatment of Raynaud's

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Emory University.
Recruitment status was  Recruiting
Information provided by:
Emory University Identifier:
First received: November 2, 2010
Last updated: November 17, 2010
Last verified: October 2010

The investigators are studying a medical condition known as Raynaud's Phenomenon (RP). RP is a painful condition in which cold surroundings or stressful events trigger pain, a cold sensation, and in severe cases, sores and ulcers on one's fingers. The investigators think that RP results from problems with some of the components of the blood vessels, surrounding nerves, and some of the circulating messengers in the bloodstream. Although there are many different medicines that are currently used to treat RP, the investigators have not yet found a cure for severe cases of this condition. Furthermore, the investigators have found few medicines that show consistent healing of the ulcers that may be associated with RP. Some of the treatments include medicines that are used to treat high blood pressure known as calcium channel blockers. Medications that thin the blood (anticoagulants) such as aspirin have also been used to treat RP.

In this study, the investigators will investigate a new treatment for RP known as Botulinum toxin A. Botulinum toxin is a chemical that is temporarily toxic to nerves, but has been approved by the government for the treatment of several other conditions including but not limited to: excessive sweating, neck pain associated with a condition known as cervical dystonia, uncontrollable forcible closure of the eyelids known as blepharospasm, and a condition known as strabismus in which the eyes are not in alignment with one another.

This study will aim to greatly improve the quality of life and pain associated with RP. Previous studies also support the chance that Botulinum toxin will help to heal some of the ulcers associated with RP. Although there is no current standard of care, many of the patients in the study will have already failed or are unable to tolerate commonly used treatments such as lifestyle modifications, calcium channel blockers, nitroglycerin, and anticoagulants. If the patient chooses to participate in the study, he/she will be randomly assigned to receive an injection with Botulinum toxin in either the left or right hand. The other hand will be injected with saline solution. Neither the patient nor the physician or research personnel seen in follow-up will know which hand is injected with Botulinum toxin.

Condition Intervention
Raynaud's Syndrome
Drug: botulinum toxin A

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Botulinum Toxin in the Treatment of Raynaud's

Resource links provided by NLM:

Further study details as provided by Emory University:

Primary Outcome Measures:
  • digital temperature [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Each digit temperature will be measured at baseline, recorded and re-measured past 20 second immersion in 4 degree C water. Temperature will continued to be measured until return to baseline.

Secondary Outcome Measures:
  • Quality of Life [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Eash participant will fill out Skindex29 questionnaire.

Estimated Enrollment: 6
Study Start Date: October 2010
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: botulinum toxin A
    Botulinum toxin A will be injected into participants hand total 40units

Ages Eligible for Study:   18 Years to 89 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:Adult (>18 years) patients with severe RP of any etiology will be invited to participate. Inclusion criteria include a) history of digital infarcts or ulcerations, b) unresponsive to standard therapies, or c) impending potential for digital amputation. Patients on other standard therapies such as antiplatelet agents, vasodilators, and calcium channel blockers will be included. -

Exclusion Criteria:Pregnancy, mild disease, patients with myasthenia gravis, botulinum toxin allergy, and phobia of needles are exclusion criteria. Women of childbearing age will need to demonstrate a negative urine pregnancy test. Myasthenia gravis is excluded because underlying generalized weakness can be exacerbated, and local weakness at injection sites can occur more than otherwise expected.


  Contacts and Locations
Please refer to this study by its identifier: NCT01233999

Contact: Bridget Bradley, RN, FNP, CCRC 404-778-3084
Contact: Rachel Sahn, MD 404-778-3178

United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Bridget R. Bradley, RN, FNP, CCRC    404-778-3084   
Contact: Rachel Sahn, MD    404-778-3178   
Principal Investigator: Suephy C Chen, MD         
Sub-Investigator: Kimberly M Neyman, MD         
Emory University Recruiting
Atlanta, Georgia, United States, 30322
Principal Investigator: Suephy C Chen, MD         
Sponsors and Collaborators
Emory University
Principal Investigator: Suephy C Chen, MD Emory University
  More Information

No publications provided

Responsible Party: Dr. Suephy Chen, Emory University Identifier: NCT01233999     History of Changes
Other Study ID Numbers: IRB00015510
Study First Received: November 2, 2010
Last Updated: November 17, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Emory University:
Raynaud's Syndrome

Additional relevant MeSH terms:
Raynaud Disease
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Botulinum Toxins, Type A
Botulinum Toxins
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses processed this record on April 16, 2014